NATCO PHARMA LIMITED (INDIA)
Sorafenat
“Sorafenat” contains the Drug / Molecule called “Sorafenib”. Sorafenib is a small molecular inhibitor of several tyrosine protein kinases. Sorafenat treatment induces catabolic mechanism that involve cell degradation; which may suppress tumor growth.
Indication
Sorafenat is used for the treatment of Primary Kidney Cancer (Advanced Renal Cell Carcinoma) and Advanced Primary Liver Cancer.
DOSAGE AND ADMINISTRATION:
Recommended daily dose is 400 mg (2 X 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
SCHEDULE H PRESCRIPTION DRUG – CAUTION
To be sold by retail on the prescription of an Oncologist only.
Note
SIDE EFFECT :
- Most commonly occurring Cardiac Ischemia, infarction, Hemorrhage, Hypertension, Hand-Foot skin reaction and rash, Gastrointestinal perforation, Wound healing complications.
INTERACTIONS :
- Interaction with Docetaxel & Doxorubicin : Sorafenat can cause increase in plasma concentration of Docetaxel & Doxorubicin
OVERDOSE :
- There is no specific treatment for Sorafenat overdose. In cases of suspected overdose Sorafenat should be withheld and supportive care instituted.
Precaution
- Sorafenat is a prescription drug and should be used under proper medical guidance and advice.
- Caution has to be taken in case of kidney / liver problems, pregnancy and lactation.
Strength
200 mg
Packing
1 X 120 Tablets (Plastic Container)
Storage
Store in a cool place, protected from light.